Physicians’ acceptance of pharmacists’ interventions in daily hospital practice by Zaal, R.J. (Rianne) et al.
Vol.:(0123456789) 
International Journal of Clinical Pharmacy 
https://doi.org/10.1007/s11096-020-00970-0
RESEARCH ARTICLE
Physicians’ acceptance of pharmacists’ interventions in daily hospital 
practice
Rianne J. Zaal1 · Edwin W. den Haak2 · Elrozy R. Andrinopoulou3 · Teun van Gelder1,4 · Arnold G. Vulto1 · 
Patricia M. L. A. van den Bemt1,5
Received: 20 May 2019 / Accepted: 6 December 2019 
© The Author(s) 2020
Abstract
Background The physicians’ acceptance rate of pharmacists’ interventions to improve pharmacotherapy can vary depend-
ing on the setting. The acceptance rate of interventions proposed by pharmacists located in the hospital pharmacy over the 
telephone and factors associated with acceptance are largely unknown. Objective To determine the physicians’ acceptance 
rate of pharmacists’ interventions proposed over the telephone in daily hospital practice and to identify factors associated 
with acceptance. Setting A retrospective case–control study was performed concerning adult patients admitted to a univer-
sity hospital in the Netherlands. Method Pharmacists’ interventions, based on alerts for drug–drug interactions and drug 
dosing in patients with renal impairment, recorded between January 2012 and June 2013 that were communicated over the 
telephone were included. Factors associated with physicians’ acceptance were identified with the use of a mixed-effects 
logistic model. Main outcome measure The primary outcome was the proportion of accepted interventions. Results A total 
of 841 interventions were included. Physicians accepted 599 interventions, resulting in an acceptance rate of 71.2%. The 
mixed-effects logistic model showed that acceptance was significantly associated with the number of prescribed drugs (16 
to ≤ 20 drugs  ORadj 1.88; 95% CI 1.05–3.35, > 20 drugs  ORadj 2.90; 95% CI 1.41–5.96, compared to ≤ 10 drugs) and the 
severity of the drug-related problem (problem without potential harm  ORadj 6.36; 95% CI 1.89–21.38; problem with potential 
harm OR 6.78; 95% CI 2.09–21.99, compared to clinically irrelevant problems), and inversely associated with continuation 
of pre-admission treatment  (ORadj 0.55; 95% CI 0.35–0.87). Conclusion Over the study period, the majority of pharmacists’ 
interventions proposed over the telephone were accepted by physicians. The probability for acceptance increased for patients 
with an increasing number of medication orders, for clinically relevant problems and for problems related to treatment initi-
ated during admission.
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Impact on practice
• The majority of pharmacists’ interventions to improve 
pharmacotherapy in a Dutch hospital are accepted by 
physicians.
• Interventions regarding pre-admission treatment are 
less likely to be accepted.
• The patient’s general practitioner should be included 
in the discussion about recommendations regarding 
chronic pharmacotherapy.
• Further insight into physicians’ reasons for non-accept-
ance is necessary to optimize central pharmacy ser-
vices.
Introduction
To prevent drug-related problems, clinical pharmacists 
review medication orders from prescribers with the use of 
a clinical decision support system (CDSS). Recommenda-
tions to optimize pharmacotherapy may then be proposed 
to the prescriber. The acceptance rate of these interven-
tions has been shown to vary between 52 and 100% [1–20]. 
This variation can be explained by differences in, among 
other things, the prescribing process (computerized or 
handwritten), the identification of potential drug-related 
problems (using CDSS or medication review), the medical 
ward (medical, surgical or intensive care unit) and the way 
of communicating the intervention (over the telephone, 
during ward rounds and/or electronically). Most previ-
ous studies on the physicians’ acceptance rate dealt with 
interventions proposed during ward rounds by clinical 
pharmacists who were a member of the multidisciplinary 
care team. However, in daily practice in the Netherlands 
and other West European countries a substantial number 
of interventions are proposed by pharmacists over the tel-
ephone. In most cases, these pharmacists are located in the 
hospital pharmacy and not at the medical ward.
A French multicentre study on pharmacists’ interven-
tions published in 2015 considered a subset of interven-
tions proposed by pharmacists from the hospital pharmacy 
over the telephone, and found that the acceptance rate 
was 62% [3]. The interventions had been extracted from 
a national database designed for documentation and clas-
sification of interventions during daily medication review. 
Since the number of interventions varied strongly between 
pharmacists, wards and hospitals, it is likely that not all 
interventions were documented.
Currently, the acceptance rate of pharmacists’ inter-
ventions communicated over the telephone is not exactly 
known. Besides, factors associated with the acceptance of 
pharmacist’s interventions proposed during daily routine 
over the telephone are little known.
Insight into the potential factors associated with accept-
ance could help optimize pharmacy services aimed at reduc-
ing drug-related problems and improving pharmacotherapy.
Aims of the study
The aims of this study were to determine the acceptance rate 
of pharmacists’ interventions proposed over the telephone in 
the Netherlands and to identify potential risk factors associ-
ated with acceptance.
Ethics approval
Since this study did not affect patient integrity, Erasmus 
Medical Center’s Medical Ethics Review Board waived 
approval for this study (Reference number MEC-2013-205).
Method
Design and setting
This study is a retrospective case–control study, performed 
in the central location of a university hospital in the Neth-
erlands with 880 beds, including 62 beds for intensive care. 
In this hospital, medication is prescribed using a computer-
ized physician order entry system  (Medicator®, CSC-Isoft, 
Leiden, The Netherlands) combined with a clinical decision 
support system, based on the Dutch national drug database 
G-standard® (Z-Index, The Hague, The Netherlands). This 
system generates intrusive alerts (pop-ups) relating overdos-
ing, duplicate therapy, allergies and drug–drug interactions. 
Alerts that are not relevant in clinical practice are turned off. 
A schematic diagram of our CDSS and the handling of alerts 
is presented in Fig. 1.
A specific set of alerts is being handled by pharmacy 
technicians. They assess the clinical relevance of the alerts 
according to local standard operating procedures. Infor-
mation on drug–drug interactions that probably require an 
intervention, other than optimizing administration times for 
pharmacokinetic drug–drug interactions which they discuss 
with the nurse, is forwarded to the pharmacists.
Reviewing alerts for drug–drug interactions is part of 
the daily routine of pharmacists in our hospital pharmacy. 
In addition, drug dosing for patients with renal impairment 
(glomerular filtration rate < 50 ml/min) is assessed with a 
clinical rule. This is an electronical tool that combines a 
patient’s characteristics, medication data and laboratory 
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values to assess the risk for drug-related problems. Our rule 
is designed to identify contra-indicated drugs for patients 
with renal impairment or the necessity of dose reduction. 
All medication orders of patients identified by this clinical 
rule are reviewed by a pharmacist.
For a patient with drug-related problems deemed clini-
cally relevant, the pharmacist in question provides a recom-
mendation to the prescriber to optimize the pharmacother-
apy—usually over the telephone. Interventions are recorded 
in the patient’s electronic medical record.
Data collection
All pharmacists’ interventions recorded in the electronic 
medical records during weekdays from January 2012 
until July 2013 resulting from drug–drug interactions and 
the clinical rule for patients with renal impairment were 
included in this study. Interventions not communicated over 
the telephone but by email were excluded from this study. 
Interventions for patients admitted to intensive care units 
were excluded as well, since a clinical pharmacist is present 
on these wards to handle alerts for these patients.
Data on the intervention (date, weekday, number of days 
since drug-related problem arose), the underlying drug-
related problem [type of drug according to the Anatomi-
cal Therapeutic Chemical (ATC) classification system and 
whether the drug had been continued from pre-admission 
treatment or was initiated during admission], patient charac-
teristics [age, gender, renal impairment (glomerular filtration 
rate < 50 ml/min), number of drugs prescribed at the time 
of intervention, length of stay at the time of intervention], 
pharmacist characteristics (gender and status: resident vs 
certified clinical pharmacist), and the prescriber’s medical 
specialty of were recorded. All patient data were processed 
anonymously in a protected database.
Drug‑related problems and interventions
Drug-related problems were classified according to the clas-
sification of Strand et al. [21], adapted by Leendertse et al. 
Computerized clinical decision support system
Assessment by pharmacy technicians




Assessment by clinical pharmacists
Drug-drug interactions
Optimization of administration times required
for pharmacokinetic drug-drug interactions
Intervention required
Communicated over the telephone
Communicated by clinical pharmacist on the 




Clinical rule for patients with renal failure*
Fig. 1  Schematic diagram of the clinical decision support system. *An electronic tool that combines medication data and laboratory values to 
detect patients with renal failure (glomerular filtration rate < 50 ml/min) at risk for drug-related problems
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[22] The adapted classification differentiates drug-related 
problems by indication (additional drug therapy required or 
unnecessary drug therapy), effectiveness (ineffective drug 
therapy or subtherapeutic dosage), safety (adverse drug 
event or supratherapeutic dosage), drug use problems, and 
pharmaceutical care issues (monitoring, drug–drug interac-
tions, contra-indicated drug, lifestyle, duplicate therapy). We 
added to this classification discrepancies between current 
treatment and pre-admission treatment as well as adminis-
trative prescribing errors (i.e. missing information on drug, 
dosage or administration route or duplicate orders).
The severity of drug-related problems was assessed using 
the National Coordinating Council for Medication Error 
Reporting and Prevention (NCC MERP) index, which clas-
sifies the severity ranging from clinically irrelevant problems 
that have the capacity to cause harm, to problems that may 
contribute to or result in death [23]. We grouped these cat-
egories into three classes, namely: clinically irrelevant drug-
related problems (NCC MERP category A); drug-related 
problems without potential harm (NCC MERP category 
B–D); and drug-related problems with potential harm (NCC 
MERP E–I), varying from mild temporary discomfort to 
death. Because actual harm had been prevented by the inter-
vention, we assessed the potential harm; i.e., possible conse-
quences of the drug-related problem, in case the pharmacist 
should not have intervened. The assessment was performed 
separately by a hospital pharmacist/clinical pharmacologists 
(PvdB) and a physician/clinical pharmacologist (TvG). They 
discussed any discrepancies until consensus was reached.
Interventions were classified as proposed by Bedouch 
et al. [24] as drug choice (addition of a drug, discontinu-
ation of a drug or drug switch), dose adjustment (increas-
ing the dose, decreasing the dose), monitoring (subdivided 
into therapeutic drug monitoring, monitoring of biochemi-
cal parameters, recording an electrocardiogram and other 
types of monitoring) and optimization of administration 
times. Based on our experience, we added a class with other 
interventions, including consulting another specialist, rec-
onciliation of pre-admission treatment, or administrative 
interventions.
Outcomes
The primary outcome was the proportion of accepted inter-
ventions. The acceptance of interventions regarding drug 
choice, dose adjustments or optimization of administration 
was assessed by reviewing the computerized physician order 
entry system. Acceptance was defined as actual implemen-
tation of the suggested change in pharmacotherapy within 
24 hours. We chose this time window because physicians 
do not always have the opportunity to change pharmaco-
therapy immediately and residents need to discuss some 
recommendations with their supervisors. Follow-up of 
recommendations regarding the monitoring of clinical chem-
ical parameters or serum drug levels or performing an elec-
trocardiogram was extracted from the medical records; inter-
ventions were considered as accepted when the suggested 
monitoring had been performed within 7 days. Monitoring 
of other adverse drug events—such as oedema, symptoms of 
heart failure or myalgia—could not be assessed in this study. 
Acceptance of these interventions was scored as unknown.
Characteristics of the intervention, the underlying drug-
related problem, patient characteristics, pharmacist charac-
teristics and the prescriber’s medical specialty were included 
as potential determinants for acceptance.
Statistical analysis
The required sample size was calculated using the rule of 
thumb that at least 10 cases are required for every variable 
included in the analysis (sample size = 10*k/p, with k the 
number of variables and p the smallest proportion of nega-
tive and positive cases). Considering an expected accept-
ance rate of 60% and 15 potential predictors, the minimum 
required sample size was 375 interventions.
Descriptive analysis was performed using IBM SPPS 
Statistics version 21. A mixed-effects logistic model was 
performed with R statistical software version 3.2.2 (www.r-
proje ct.org) to investigate associations between potential 
determinants and acceptance, while accounting for multiple 
interventions within the same patients. The advantage of 
using mixed-effect models is that they can deal with unbal-
anced datasets, i.e. when the number of observations, which 
could be registered at different time points, per patient var-
ies. This model was chosen because the acceptance of an 
intervention for a given patient could have been influenced 
by previous interventions for this patient. To ease the inter-
pretation, the continuous variables age, number of drugs and 
length of stay were categorized into four categories, based 
on the quartiles of their frequencies. Adjusted odds ratios 
 (ORadj), corrected for the other covariates, with 95% confi-
dence intervals (95% CI) were calculated. A p value < 0.05 
was considered statistically significant.
Results
Data on 841 interventions, involving 623 patients, were 
included. Characteristics of these interventions and patients 
are presented in Table 1. Drug–drug interactions (46.4%), 
supratherapeutic dosages (21.8%) and requirement of addi-
tional drug therapy (8.7%) were the most common underly-
ing drug-related problems (Table 2). Interventions were pro-
posed most frequently for problems related to anti-infective 
agents (33.9%), drugs acting on blood and blood forming 
organs (13.4%), and drugs acting on the alimentary tract 
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and metabolism (12.2%) (Table 3). As 599 of the 841 inter-
ventions had been accepted, the physicians’ acceptance rate 
was 71.2%.  
The two clinical pharmacologists assessed 569 (67.7%) 
drug-related problems as clinically relevant problems with 
the potential to cause harm to the patient, whereas 253 
(30.1%) of the problems were assessed as unlikely to cause 
harm. Nineteen (2.3%) problems were considered as clini-
cally irrelevant.
The mixed-effects logistic model used to explore asso-
ciations between potential risk factors and acceptance is 
presented in Table 4. Physicians’ acceptance was statisti-
cally significantly associated with the number of prescribed 
drugs (16 to ≤ 20 drugs  ORadj 1.88; 95% CI 1.05–3.35, > 20 
drugs  ORadj 2.90; 95% CI 1.41–5.96) and with the severity 
of the drug-related problem (drug-related problems without 
potential harm  ORadj 6.36; 95% CI 1.89–21.38; drug-related 
with potential harm  ORadj 6.78; 95% CI 2.09–21.99), and 
inversely associated with continuation of pre-admission 
treatment  (ORadj 0.55; 95% CI 0.35–0.87).
Discussion
In this study, the physicians’ acceptance rate of pharma-
cists’ interventions was 71.2%. Acceptance was statistically 
significantly associated with the number of medication 
orders at the time of the intervention, the continuation of 
pre-admission treatment and the severity of the underlying 
drug-related problem.
This acceptance rate is somewhat higher than the accept-
ance rate of 62% found in the French multi-centre study 
referred to in the introduction section [3]. Others have 
reported even lower acceptance rates of around 50% [6, 12, 
13]. The higher acceptance rate found in our study could 
perhaps be explained by the accurate assessment of the 
clinical relevance of potential drug-related problems by our 
pharmacists, illustrated by the small number of clinically 
irrelevant alerts.
In addition, differences such as the communication meth-
ods, the system for detecting the drug-related problems and 
physicians’ attitude towards pharmacists between the studies 
could have contributed to the discrepant acceptance rates.
The acceptance rate in our study is comparable with some 
reported acceptance rates of around 60% to 80% in settings 
where pharmacists have been integrated in the medical team 
on the ward [3, 13, 17, 18, 25]. Therefore, central checking 
of CDSS alerts and clinical rules might be commendable, 
also for settings with pharmacists on the ward, so that these 
pharmacist can focus on other drug-related problems, such 
as adverse drug reactions.
Table 1  Characteristics of included patients and interventions 
included
a DRPs drug-related problems
n (%)
Patients 623 (100.0)
  Female gender 263 (42.2)
Age in years, median (range) 64.0 [18–91]
DRPsa per patient, median (range) 1.0 [1–6]
Proposed interventions 841 (100.0)
Table 2  Drug-related problems underlying pharmacists’ interventions 
(n = 841)
DRP drug-related problem
Class Subclass of DRP n (%)
Indication Additional drug therapy 
required
73 (8.7)
Unnecessary drug therapy 3 (0.4)
Effectiveness Ineffective drug therapy 8 (1.0)
Dosage too low 45 (5.4)
Safety Dosage too high 183 (21.8)
Adverse drug event 8 (1.0)
Drug use Drug use problem 13 (1.5)
Pharmaceutical care Drug-drug interaction 390 (46.4)
Contra-indication 64 (7.6)
Duplicate therapy 25 (3.0)
Monitoring 11 (1.3)







Table 3  Pharmacotherapeutic drug group underlying pharmacists’ 
interventions (n = 841)
a According to Anatomical Therapeutic Chemical (ATC) classification 
system
b Includes dermatologicals (D), genito-urinary system and sex hor-
mones (G), systemic hormonal preparations (H), antiparasitic prod-
ucts (P) and respiratory system (R)
Pharmacotherapeutic  groupa n (%)
Alimentary tract and metabolism (A) 103 (12.2)
Blood and blood forming organs (B) 113 (13.4)
Cardiovascular system (C) 69 (8.2)
Anti-infective agents for systemic use (J) 285 (33.9)
Antineoplastic and immunomodulating agents (L) 33 (3.9)
Musculo-skeletal system (M) 94 (11.2)
Nervous system (N) 86 (10.2)
Otherb 58 (6.9)
Total 841 (100.0)
 International Journal of Clinical Pharmacy
1 3
Table 4  Association between 
potential risk factors and 
acceptance of pharmacists’ 
interventions (n = 769)a
Potential risk factor ORadj 95% CI p-value
Characteristics of intervention
Sequential count of interventions per patient 1.00 0.77–1.31 0.976
Type of intervention
  Addition of a drug Ref.
  Discontinuation of a drug 1.17 0.45–3.03 0.745
  Drug switch 0.57 0.25–1.27 0.168
  Increasing the dose 0.75 0.26–2.16 0.588
  Decreasing the dose 0.81 0.33–2.01 0.653
  Therapeutic drug Monitoring 0.47 0.16–1.41 0.179
  Monitoring of biochemical parameters 0.53 0.19–1.45 0.219
  Recording an electrocardiogram 0.33 0.10–1.08 0.067
  Optimization of administration times 1.06 0.33–3.57 0.930
Weekday of intervention
  Monday Ref.
  Tuesday 2.34 0.88–6.20 0.087
  Wednesday 1.24 0.69–2.22 0.473
  Thursday 0.83 0.45–1.50 0.532
  Friday 0.94 0.51–1.74 0.852
Number of days since problem arose 0.93 0.76–1.14 0.477
Characteristics of underlying drug-related problemb
Pharmacotherapeutic group of drug involved
  Alimentary tract and metabolism (A) Ref
  Blood and blood system (B) 0.72 0.33–1.60 0.423
  Cardiovascular system (C) 1.05 0.44–2.49 0.912
  Anti-infectives for systemic use (J) 0.84 0.41–1.69 0.628
  Antineoplastics and immunomodulating agents (L) 0.43 0.15–1.26 0.123
  Musculo-skeletal system (M) 0.58 0.26–1.30 0.185
  Nervous system (N) 0.65 0.27–1.52 0.320
  Otherc 0.57 0.23–1.41 0.220
Severity
  Clinically irrelevant drug-related problem Ref.
  Relevant problem without potential harm 6.36 1.89–21.38 0.002
  Relevant problem with potential harm 6.78 2.09–21.99 0.001




Female gender 0.86 0.58–1.27 0.443
Age (years)
  ≤ 50 0.66 0.38–1.13 0.126
  51 to ≤ 65 0.91 0.50–1.65 0.759
  66 to ≤ 75 0.92 0.47–1.79 0.796
  > 75
Presence of renal impairment 1.10 0.70–1.73 0.676
Number of drugs
  ≤ 10 Ref.
  11 to ≤ 15 1.63 0.94–2.81 0.082
  16 to ≤ 20 1.88 1.05–3.35 0.033
  > 20 2.90 1.41–5.96 0.004
Length of stay (days)
  ≤ 1 ref.
  2 to ≤ 3 0.65 0.38–1.12 0.123
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In our study, the number of prescribed drugs of a patient 
at the time of the intervention was significantly associ-
ated with acceptance. This may be related to the possibil-
ity of physicians having insufficient overview of a patient’s 
pharmacotherapy with a higher number of medication 
orders—and then are more inclined to accept a pharmacist’s 
intervention. This suggests an added value of the input of 
pharmacists for patients with polypharmacy, which is a well-
known risk factor for drug-related problems [26].
Furthermore, the probability for acceptance decreased if 
the underlying drug had already been initiated before admis-
sion, which suggests that physicians may be reluctant to 
change the medication, initiated by another physician before 
admission, on which a patient has been stable on.
Our finding that interventions for drug-related problems 
assessed as clinically relevant are more likely to be accepted 
suggests that physicians carefully consider the clinical rel-
evance of a problem—weighing the risks and benefits for 
the individual patient. On the other hand, their tendency not 
to accept clinically irrelevant interventions was in line with 
the clinical pharmacologist’s assessment.
We did not find an association between acceptance and 
any other characteristics of the intervention, the underly-
ing problem, the patient or the prescriber. In addition, we 
found no difference in acceptance rates between pharmacy 
residents and certified hospital pharmacists, indicating that 
our residents are well trained to review pharmacotherapy 
and propose interventions. It may well be, however, that the 
physicians are not aware of the professional status of the 
pharmacist who proposed the intervention. Still, the find-
ing that some of the drug-related problems were assessed 
as clinically irrelevant by clinical pharmacologists shows 
variability between different professionals with regard to 
the medication review process, despite training and use of 
guidelines.
In contrast to our results, Bedouch et al. [3] showed a sig-
nificant association between several therapeutic drug classes 
and acceptance. Besides, some previous studies have shown 
differences in acceptance between surgical and medical 
wards [3, 8, 27]. We were not able to reproduce the results 
of these studies, which can probably be explained by differ-
ences in setting and the smaller sample size of our study.
In our setting, interventions were discussed between 
the pharmacist and the physician over the telephone and 
recorded in the patient’s electronic medical record. In our 
study, the pharmacy tab in the electronic medical records of 
the 623 included patients was viewed 5568 times in total; in 
96.9% of cases by a pharmacist and in only 3.1% of cased 
by a physician. This indicates that physicians’ decisions to 
accept interventions generally are based on the discussion 
with the pharmacist, since they hardly viewed the recorded 
recommendations. Previous studies indeed have shown that 
verbally communicated interventions are much more likely 
to be accepted than interventions that are only recorded 
electronically [6, 25]. These findings support the feasibility 
and safety of pharmacists located in the hospital pharmacy 
proposing interventions for drug-related problems over the 
telephone.
Several limitations of our study need to be addressed. 
First, physician’s reasons for not accepting, that could 
have been discussed during the phonecall, had not been 
recorded systematically in the electronic records. There-
fore, we could not assess whether there was a valid argu-
ment for not accepting the intervention in this study. In a 
Figures in bold are statistically significant
OR odds ratio, CI confidence interval, Ref. reference, DRP drug-related problem
a Excluding interventions for which acceptance could not be assessed (n = 51). Subsequently, interventions 
with missing data [renal function (n = 11) and continuation of pre-admission treatment (n = 6)] and inter-
ventions for intensive care units (n = 1) and intervention types “consulting another specialist” (n = 2) or 
“administrative interventions” (n = 1) were excluded from the mixed-effects model as well
b According to Anatomical Therapeutic Chemical (ATC) classification system
c Includes dermal preparations (D), genito-urinary system and sex hormones (G), systemic hormonal prepa-
rations (H), antiparasitic products (P) and respiratory system (R)
Table 4  (continued) Potential risk factor ORadj 95% CI p-value
  4 to ≤ 8 0.98 0.54–1.76 0.936
  > 8 0.80 0.44–1.46 0.461
Pharmacists’ characteristics
Female gender 1.53 0.89–2.60 0.122
Residents (certified hospital pharmacists are reference) 0.95 0.62–1.45 0.804
Prescriber’s medical specialty
  Medical Ref.
  Surgical 1.14 0.71–1.84 0.589
  Cardiology 1.09 0.65–1.82 0.754
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future prospective study, it may be commendable to record 
physicians’ argumentations.
Second, the proportion of the proposed interventions in 
relation to the total number of CDSS alerts is unknown. In 
a previous study only 1.6% of all alerts required a pharma-
cist intervention [13]. This proportion could vary between 
different pharmacists and settings and could influence the 
acceptance rate. For example, the acceptance rate would 
perhaps be higher if the pharmacists decide to propose 
only the most urgent interventions. Given the small num-
ber of clinically irrelevant problems in our study, it is 
likely that all pharmacists involved focused on the most 
relevant problems and that differences between pharma-
cists had no significant effect on the acceptance rate.
Third, this study was performed in a single center. The 
findings may be difficult to extrapolate to other hospitals, 
especially those where the pharmacists have been more 
integrated in the ward medical. Fourth, we were not able 
to include any characteristics of the prescribers, except for 
specialty. In a previous study, physician’s status (resident 
vs specialist) has been associated with acceptance [25]. 
Besides, we could not determine whether an intervention 
was proposed to the initial prescriber or to another phy-
sician. It is not unthinkable that the acceptance rate can 
be influenced by proposing an intervention to the initial 
prescriber or to another physician.
Despite these limitations, the findings of this study may 
be of value to hospitals with central pharmacy services, 
where pharmacists are not integrated in the medical teams 
on the ward, to optimize their services and reduce drug-
related problems.
Prospective follow-up of interventions and exploring 
physicians’ reasons for non-acceptance are recommended 
for future research, with the ultimate goal to minimize 
interventions that are irrelevant given the patient’s current 
medical condition. Furthermore, clinical consequences of 
non-acceptance in terms of patient harm, length of stay 
and pharmaceutical costs need to be studied.
To improve clinical pharmacy services, pharmacists and 
physicians in primary and secondary care should agree on 
their responsibilities on chronic pharmacotherapy during 
a patient’s admission, as we found that physicians tend 
to decline interventions regarding medication initiated 
before admission. Non-urgent recommendations could be 
discussed together with a patient’s general practitioner. 
Stronger arguments should be used to increase the accept-
ance of interventions for patients using fewer than 10 pre-
scribed drugs. On the other hand, pharmacists could more 
pro-actively review the pharmacotherapy of patients using 
more than 15 prescribed drugs, to detect additional drug-
related problems and optimize therapy together with the 
physician.
Conclusion
In conclusion, during the period under study, most of the 
pharmacists’ interventions communicated over the tel-
ephone were accepted by the physicians. The probability 
of acceptance increased for patients with an increasing 
number of medication orders, for patients with relevant 
drug-related problems and for patients whose drug treat-
ment had been initiated during admission. To optimize 
pharmacy services, further insight into physicians’ reasons 
for non-acceptance should be obtained.
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